Cara therapeutics, inc. (CARA)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Operating activities
Net loss

-106,373

-74,013

-58,125

-57,280

-24,690

-17,745

-3,963

-6,271

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense

12,568

9,478

5,793

2,800

2,514

1,371

123

61

Modification of equity awards

-

-616

-537

-

-

-

-

-

Depreciation and amortization

198

370

495

1,465

839

783

789

1,021

Amortization expense component of lease expense

601

-

-

-

-

-

-

-

Noncash expense related to oral formulation license agreement

4,000

-

-

-

-

-

-

-

Accretion of available-for-sale marketable securities, net

1,381

1,820

582

218

18

-

-

-

Realized loss (gain) on sale of available-for-sale marketable securities

-

-5

5

23

-

-

-

-

Amortization of financing costs

-

-

-

-

-

-

117

4

Realized gain on sale of property and equipment

-

-

41

-

-

-

-

-286

Deferred rent costs

-

156

-148

114

289

265

238

214

Deferred revenue

-19,747

42,009

-

-

-1,452

-2,023

3,475

-

Change in fair value of liability under license agreement

-

-

-

-

-

-

35

25

Accrued interest and amortization of beneficial conversion feature on promissory notes

-

-

-

-

-

-

3,605

25

Loss on write-off of fixed assets

-

-

-

-

-2

-

-

-

Changes in operating assets and liabilities:
Income tax receivable

152

-67

-121

468

184

139

30

-8

Other receivables

45

803

36

7

80

-

-

-18

Prepaid expenses

4,058

3,170

105

-199

1,442

-388

1,736

-73

Restricted cash

-

-

-

-

-

-

-

-294

Accounts payable and accrued expenses

6,043

5,116

-3,027

6,265

3,322

-12

722

-1,311

Operating lease liability

-879

-

-

-

-

-

-

-

Net cash used in operating activities

-109,225

-22,301

-54,827

-47,381

-21,478

-17,642

2,829

-6,031

Proceeds from maturities of available-for-sale marketable securities

253,584

175,300

82,156

80,380

-

-

-

-

Proceeds from sale of available-for-sale marketable securities

-

79,808

8,755

34,003

-

-

-

-

Proceeds from the redemptions of available-for-sale marketable securities, at par

2,000

-

-

-

-

-

-

-

Purchases of available-for-sale marketable securities

286,082

337,854

127,394

68,648

91,657

-

-

-

Purchases of property and equipment

18

73

58

717

20

42

5

-

Proceeds from sale of property and equipment

-

-

41

-

-

-

-

511

Net cash provided by investing activities

-30,516

-82,819

-36,500

45,018

-91,677

-42

-5

511

Proceeds from initial public offering, net of issuance costs

-

-

-

-

-

57,762

-

-

Proceeds from the sale of common stock in a follow-on public offering, net of issuance costs

136,498

92,063

86,224

-

75,231

-

-

86

Proceeds from the sale of common stock under license agreement

-

14,556

-

-

-

-

-

-

Proceeds from convertible promissory notes

-

-

-

-

-

-

1,462

2,538

Financing costs on convertible promissory notes

-

-

-

-

-

-

70

47

Repayment of convertible promissory notes

-

-

-

-

-

-

311

-

Repayment of long-term debt

-

-

-

-

-

-

307

446

Proceeds from sale of common stock

-

-

-

-

-

100

-

-

Proceeds from the exercise of stock options

6,106

4,194

1,699

123

362

128

-

55

Net cash provided by financing activities

142,604

110,813

87,923

123

75,593

57,990

8,416

2,540

Net decrease in cash, cash equivalents and restricted cash

2,863

5,693

-3,404

-2,240

-37,562

40,306

11,240

-2,980

Cash paid for interest

-

-

-

-

-

-

37

20

Shares of common stock issued in connection with oral formulation license agreement

4,000

-

-

-

-

-

-

-

Shares of common stock issued in exchange for consulting services

197

-

-

-

-

-

-

-

Conversion of convertible preferred stock to common stock

-

-

-

-

-

65,586

-

-

Reclassification of prepaid IPO costs paid in 2013

-

-

-

-

-

1,465

-

-

Tenant improvements paid by landlord

-

-

-

1,094

-

-

-

-

Conversion of convertible promissory notes to Series D convertible preferred stock

-

-

-

-

-

-

3,888

-